• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    4/24/24 4:31:44 PM ET
    $ACRV
    $AIH
    $AKLI
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACRV alert in real time by email

    Gainers

    • Acrivon Therapeutics (NASDAQ:ACRV) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million.
    • Amarin Corp (NASDAQ:AMRN) stock moved upwards by 8.12% to $0.95. The company's market cap stands at $381.2 million.
    • Universe Pharmaceuticals (NASDAQ:UPC) stock rose 7.47% to $2.3. The market value of their outstanding shares is at $8.3 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 7.14% to $0.34.
    • Telesis Bio (NASDAQ:TBIO) shares moved upwards by 7.12% to $0.34. The company's market cap stands at $10.3 million.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 6.98% to $0.49. The market value of their outstanding shares is at $23.3 million.

    Losers

    • Akili (NASDAQ:AKLI) shares decreased by 11.3% to $0.22 during Wednesday's after-market session. The company's market cap stands at $17.2 million.
    • BiomX (AMEX:PHGE) shares fell 5.24% to $0.32. The company's market cap stands at $17.7 million.
    • OneMedNet (NASDAQ:ONMD) stock fell 4.84% to $0.55. The company's market cap stands at $13.1 million.
    • Dare Bioscience (NASDAQ:DARE) shares decreased by 3.68% to $0.28. The company's market cap stands at $27.7 million.
    • Mereo BioPharma Group (NASDAQ:MREO) stock fell 3.6% to $2.68. The company's market cap stands at $375.8 million.
    • Biomarin Pharmaceutical (NASDAQ:BMRN) shares fell 3.49% to $88.02. The market value of their outstanding shares is at $16.7 billion. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRV
    $AIH
    $AKLI
    $AMRN

    CompanyDatePrice TargetRatingAnalyst
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/28/2026$80.00Overweight
    Barclays
    BioMarin Pharmaceutical Inc.
    $BMRN
    1/20/2026$98.00Hold → Buy
    Canaccord Genuity
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    BioMarin Pharmaceutical Inc.
    $BMRN
    12/3/2025$60.00Outperform → Market Perform
    Leerink Partners
    BioMarin Pharmaceutical Inc.
    $BMRN
    11/6/2025$61.00Buy → Hold
    Stifel
    BioMarin Pharmaceutical Inc.
    $BMRN
    9/8/2025$60.00Neutral
    H.C. Wainwright
    BioMarin Pharmaceutical Inc.
    $BMRN
    9/3/2025$85.00Outperform
    Raymond James
    More analyst ratings

    $ACRV
    $AIH
    $AKLI
    $AMRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

    For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

    6/29/23 6:02:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on BioMarin Pharmaceutical with a new price target

    Barclays resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $80.00

    1/28/26 7:15:50 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioMarin Pharmaceutical upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded BioMarin Pharmaceutical from Hold to Buy and set a new price target of $98.00

    1/20/26 8:41:11 AM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fishman Peter L.

    4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

    4/2/26 4:30:11 PM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Davis George Eric

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    3/19/26 4:53:12 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Guyer Charles Greg

    4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)

    3/19/26 4:50:54 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data

    MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet's rapidly growing network. 2025 Financial Highlights: RWD Revenue Growth: RWD revenue increased 329% year-over-year, rising from $292,000 in 2024 to $1,254,000 in 2025, reflecting strong market demand and increased commercial traction.

    4/6/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI

    MINNEAPOLIS, April 01, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a collaboration with OneMedNet Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet's iRWD™ platform— powered by Palantir (PLTR) Foundry— providing it access to U.S. real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and re

    4/1/26 8:55:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BiomX Obtains Option to Acquire Control of Israeli Laser-Radar Counter-Drone System

    NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of proprietary LADAR (Laser Radar)–based detection systems for security, defense, and critical infrastructure applications. DFSL's LADAR technology combines laser-based sensing with proprietary AI algorithms to detect and respond to both UAV and ground-based intruders. BiomX intends to exercise the option subject to the closing of the underlying agreement and obtaining shareholder approval as necessary or consideration consisting of a combination of cash, promissory note, shares of common stock and warrants. Separat

    3/31/26 10:48:41 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Devroe Eric bought $17,218 worth of shares (10,000 units at $1.72), increasing direct ownership by 15% to 75,308 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/15/26 4:38:05 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    SEC Filings

    View All

    SEC Form QUALIF filed by Dare Bioscience Inc.

    QUALIF - Dare Bioscience, Inc. (0001401914) (Filer)

    4/2/26 12:15:02 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by China Pharma Holdings Inc.

    10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:15:23 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by China Pharma Holdings Inc.

    NT 10-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    4/1/26 4:05:03 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 4:18:45 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 3:30:42 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 11:44:32 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioMarin Appoints Arpit Davé Chief Digital and Information Officer

    Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across the Biopharmaceutical Industry SAN RAFAEL, Calif., Jan. 12, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced it has appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, a new position reporting directly to President and Chief Executive Officer Alexander Hardy. Mr. Davé will be responsible for reimagining and executing BioMarin's enterprise technology strategy, data science and digital transformation to help create value for patients, employees and shareholders.

    1/12/26 4:05:00 PM ET
    $BMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    $AIH
    $AKLI
    $AMRN
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update

    Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

    3/26/26 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care